US 9,851,358 B2 · Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination

Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination

AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paul Sabatier Toulouse III, Centre Hospitalier Universitaire De Toulouse, Universite De Bourgogne, Universite De Rennes I, Universit des Antilles et de la Guiyane, éCole Des Hautes éTudes En Santé Publique (Ehesp)

InventorsPatrick Legembre, Bruno Segui, Thierry Levade, Olivier Micheau

Life of this patent

Estimating the term…

Abstract

The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.

Claims5

Dependent claims

A method for inhibiting or reducing metastatic dissemination in a subject suffering from a cancer comprising the steps of:

i) measuring an expression level of at least one biomarker selected from the group consisting of:
soluble CD95L and epithelial-to-mesenchymal transition (EMT) promoting factors in a sample obtained from the subject,
ii) comparing the expression level measured at step i) with a reference expression level of the biomarker determined in an individual who has the same cancer but for whom metastatic dissemination did not occur, and
iii) administering to the subject a therapeutically effective amount of at least one compound selected from the group consisting of C16-ceramide, C16-sphingomyelin and C16-glycosphingolipid when the expression level determined at step i) is higher than the reference biomarker expression level.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

15/109,942Filed 7 Jan 2015

Priority

EP 143050198 Jan 2014

Published

US 2016/0327561 A110 Nov 2016

Granted

26 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

G01N 33/5758
For cancer: involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress…
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/164
Amides, e.g. hydroxamic acids: of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61P 35/00
Antineoplastic agents